Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401692 | 0.82 | CA1 (0.63) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL11207523 | 0.80 | CA1 (0.61) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL9587172 | 0.79 | TSHR (0.61) | HSD17B10ALDH1A1TSHRSMN1; SMN2CASP1 | |
| SCHEMBL31568534 | 0.79 | TSHR (0.61) | HSD17B10ALDH1A1TSHRSMN1; SMN2CASP1 | |
| SCHEMBL132175 | 0.77 | CA1 (0.69) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL7085459 | 0.76 | CA1 (0.67) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL9555501 | 0.76 | NOX1 (0.47) | ALDH1A1CYP3A4TSHRSMN1; SMN2CASP1 | |
| SCHEMBL4093981 | 0.75 | KDM4E (0.43) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL27612735 | 0.74 | CA1 (0.54) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL9586283 | 0.74 | TP53 (0.61) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1187605-A4 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6462086-B1 | SUCH AS FARNESYLTHIOSALICYLIC ACID; INHIBITING PROLIFERATION OF T-CELLS; DIABETES, LUPUS, MULTIPLE SCLEROSIS; GRAFT REJECTION INDUCED BY FOREIGN ANTIGENS; CIRRHOSIS, RESTENOSIS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-10-08 | — | — | US | disclosed |
| EP-1187605-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Thyreos Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078303-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0026000-B1 | SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-05-11 | — | — | EP | disclosed |
| US-4362740-A | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-12-07 | — | — | US | disclosed |
| EP-0026000-A1 | Spiro compounds, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | HSD17B10 648/4885ALDH1A1 273/4885CYP3A4 1744/4885 |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RSU1, KSR1, KRAS | HSD17B10 4164/4885ALDH1A1 4061/4885CYP3A4 4608/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | HSD17B10 2065/4885ALDH1A1 888/4885CYP3A4 1595/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | HSD17B10 648/4885ALDH1A1 273/4885CYP3A4 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.